CRA advised counsel and presented before the FTC on transactions involving Novartis’ acquisition of cancer drugs from GlaxoSmithKline, GSK’s joint venture with Novartis on consumer health, and Novartis’s sale of Novartis Animal Health to Eli Lilly & Co. The deals ultimately went forward with certain divestitures.
IP Literature Watch: November 2022
Among the pieces featured in this month’s IP Literature Watch are a paper providing an overview of the competition law challenges that must be addressed in the...